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Typing of hepatitis C virus (HCV) isolates from Argentine patients was performed by using different meth-
odologies in a population of 243 patients. HCV subtype was assigned based upon restriction fragment length
polymorphism (RFLP). HCV RNA genomes obtained from serum samples were classified as belonging to clade 1
(53.5%), 2 (23.0%), or 3 (8.6%); 14.8% of samples showed HCV mixed infections, more frequently implying
different subtypes within the same clade. In addition to RFLP typing, phylogenetic relatedness among sequences
from both 5* untranslated region (n 5 50) and nonstructural 5B coding region (n 5 15) was established.
Hepatitis C virus (HCV), the causative agent of most cases
of non-A, non-B hepatitis, exists as a heterogeneous group of
viruses sharing at least 65% homology among different strains.
This virus has a positive-sense, single-stranded RNA genome
of approximately 9.5 kb. There are three functional regions of
the genome, the 59 untranslated region (59UTR), the coding
region encoding the structural and nonstructural viral proteins,
and the 39UTR. When different strains of HCV are compared,
nucleotide sequence variation is unevenly distributed through-
out the genome, ranging from segments within the coding
regions with high variability (such as for envelope proteins) to
the highly conserved 59UTR region. Sequence analysis per-
formed on isolates from different geographic areas around the
world has revealed the presence of six genetic clusters which
have been recently classified as clades 1 to 6 (42).
Several methodologies have been developed for identifica-
tion of genetic groups of HCV. Among them, two noncom-
mercial ones are widely used when a large number of samples
are being studied: restriction fragment length polymorphism
(RFLP) analysis of PCR amplicons from the 59UTR (9) and
core-based PCR typing (28, 30, 31). However, the subtype
assignment is strongly recommended to be based upon se-
quence analysis on HCV coding regions such as core, E1 or
NS5B (42).
Since data regarding HCV genomic characteristics from
South America are still scarce, the aim of the present study was
to characterize the clade and subtype distribution of different
isolates from chronically HCV-infected Argentine patients. To
reach this goal, three different methodologies were used, in-
cluding cDNA sequencing and phylogenetic analysis of se-
lected samples, supported by bootstrap resampling.
MATERIALS AND METHODS
Patients. From 1993 to 1999 we characterized 243 HCV isolates from three
different groups of viremic patients (nonhemophiliac and naive of antiviral ther-
apy). The first group comprised 129 patients with parenteral risk of viral infec-
tion, including 56 blood transfusion patients, 40 intravenous drug users (IVDU),
15 hemodialysis patients, and an additional 18 individuals who had a history of
potential parenteral routes for viral exposure (undergoing surgery, having a
tattoo or acupuncture, being a laboratory professional, or practicing homosexual
behavior). The second group (n 5 8) included patients with nonparenteral risk
(either having nonmarital household contact with an infected individual or being
a drug addict who uses oral or nasal routes of drug entry). The third group (n 5
106) was composed of sporadic or community-acquired cases. The mean age 6
standard deviation (SD) in the whole study group was 43.3 6 24.8 years (range,
2 to 73 years), with a gender distribution showing male predominance (60.5%).
Age ranges were not equally represented among different groups of patients. The
mean 6 SD, median, and range (1st to 3rd quartile) for each group were,
respectively, as follows: for transfused patients, 24.6 6 21.2, 16, and 8 to 36; for
IVDU, 33.3 6 10.2, 30, and 26.5 to 35.5; for dialyzed patients, 28.4 6 14.4, 31,
and 21 to 35; for sporadic cases, 50.0 6 17.4, 55.0, and 39.5 to 64; for health
workers, 47.9 6 9.5, 45, and 41 to 56; for other parentally infected patients,
41.6 6 20.0, 44.5, and 30.7 to 58.7; and, lastly, for other nonparentally infected
patients, 43.0 6 10.1, 39, and 38.2 to 43.7.
Informed consent to participate in the study was provided by all patients or
their parents. Two hundred twenty-five patients were adults, and 18 were pedi-
atric patients. All serum samples were analyzed by 59UTR RFLP. In addition,
selected cases were studied using other methodologies, as shown in Table 1.
Serum alanine aminotransferase (ALT) levels were determined by using a
commercial kit (BioSystems) according to the manufacturer’s instruction. Nor-
mal ALT levels were #35 U/liter when testing was done at 37°C.
RNA extraction, RT-nested PCR of the 5*UTR, and RFLP analysis. RNA was
extracted from 200 ml of serum using guanidinium isothiocyanate and acidic
phenol followed by reverse transcription (RT)-nested PCR amplification of the
59UTR as previously described (33). The HCV 59UTR amplicons obtained (210
bp) were characterized by RFLP (9) as modified by the authors (33, 39, 41). This
procedure was applied to the whole population analyzed (Table 1).
PCR amplification of other genome regions. Core-based genotyping was per-
formed as previously described (33) and was initially used to analyze HCV strains
from 56 consecutive patients included within this study (core PCR [Table 1]).
This methodology was subsequently discontinued, since a significant percentage
of the isolates could not be typed. For selected samples an improved version of
this method was employed in order to detect the HCV 2c subtype (26).
RT-nested PCR amplification of an NS5B fragment (nucleotides 7975 to 8196)
as previously described (6, 11) was performed on 34 samples selected because
they (i) had discrepant results between core-based genotyping and 59UTR RFLP
(n 5 6), (ii) were nontypeable by the core-based methodology (n 5 26), or (iii)
had unrecognized RFLP patterns within the 59UTR, resulting in inconclusive
subtype assignment (n 5 2). Since only 56 specimens had been previously tested
by the core-based RT-nested PCR, we cannot rule out the possibility that more
specimens would have yielded discrepant results between such a method and
59UTR RFLP.
5*UTR-core RFLP. In order to confirm mixed infections involving subtypes 1a
and 1b detected by 59UTR RFLP, amplicons of 647 bp partially encompassing
both the 59UTR and the core were obtained by RT-heminested PCR using
primers HCV2 (outer sense), HCV4 (inner sense), and 186 (antisense) as de-
scribed previously (33, 41), using the same cycling conditions reported for core-
based PCR (33). Bands of the expected size were purified and digested for 6 h
with AccI. As reported elsewhere (2, 3), this endonuclease recognizes two re-
striction sites within 1a amplicons (fragments of 225, 192, and 230 bp) and one
restriction site within 1b (or 1c) amplicons (fragments of 225 and 417 bp) (Fig.
1).
Avoidance of PCR contamination. PCR amplification of all three genome
regions (59 UTR, core, and NS5B) strictly followed the recommendations of
Kwok and Higuchi (21). In addition, different sets of micropipettes and special
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aerosol-resistant tips (Molecular Bio-Products, Inc.) were used for each proce-
dure from serum collection to agarose gel analysis of the PCR products. To
validate results, a negative control was included from the extraction step for
every four samples, and another negative control was also added from RT. A
positive control was included from RNA extraction. Separate rooms were used
for PCR preamplification, amplification, and gel loading. Mixed infections were
confirmed by duplicate analysis from two different serum aliquots.
Sequencing of 5*UTR and NS5B amplicons. The 59UTR (n 5 50) and NS5B
(n 5 15) PCR products were purified as previously described (40), and the
fragments were sequenced (43) using both sense and antisense primers with 59
-end-fluorescent-labeled dideoxynucleotides in an automatic sequencer (ABI
373A; Applied Biosystems, Foster City, Calif.). To avoid misinterpretations, each
template was obtained from at least two different aliquots of RNA and se-
quenced bidirectionally.
Selected samples for 59UTR cDNA sequencing were (i) 13 out of the 33
samples which had exhibited either nontypeable (n526) or discrepant results
compared with 59UTR RFLP (n 5 7), according to the core-based typing meth-
od; and (ii) 37 others representative of the different groups studied, including
parenteral risk of infection (n 5 25), nonparenteral risk (n 5 7), and sporadic
cases (n 5 5). The above-mentioned set of 13 samples was randomly selected in
order to test the accuracy of data already obtained by 59UTR RFLP (Table 1).
Phylogenetic methods. The clade and subtype for each sample was determined
by sequence comparison with prototypic strains followed by further phylogenetic
analysis. The DNA alignments were generated with the Clustal X program (48).
Evolutionary distances between sequences were determined with the DNADIST
program (Kimura two-parameter method) of the PHYLIP package, version 3.5c
(13). The phylogenetic tree was constructed with the TREEVIEW program, as
previously described (40). Bootstrap analysis was performed by using the pro-
grams SEQBOOT (to generate 1,000 reshuffled sequences), CONSENSE, and
RETREE at the midpoint of the longest branch for comparative purposes.
HCV serologic genotyping. Selected samples (n 5 3) showing mixed infections
ascribed to different genotypes were studied by enzyme-linked immunosorbent
assay by means of a commercial test to detect antibodies against type-specific
HCV NS4 peptides (MUREX HCV, Serotyping 1–6 Assay; Murex, Buenos
Aires, Argentina).
Statistical analysis. Statistical differences were calculated by means of para-
metric tests (comparison of two sample proportions or Student’s t test) or
nonparametric tests (by the chi-square test with Yates’ correction, and by Fish-
er’s exact test when 8 # N # 75, where N is the sum of the values in a given
table). Tadpole III program (Biosoft, Cambridge, United Kingdom) was used
throughout this study. The median age and the 1st and 3rd quartile range from
each population group were calculated by using the Excel program from the
Office 97 Microsoft package.
Nucleotide sequence accession numbers. Nucleotide sequence data reported
in this paper were deposited in the GenBank database with the following acces-
sion numbers: AF041264 to AF041313 (59UTR sequences) and AF041314 to
AF041328 (NS5B sequences).
RESULTS
RFLP analysis of 5*UTR amplicons. Out of 243 samples,
clade 1 was detected in 130 (53.5%), clade 2 was detected in 56
(23.0%), and clade 3 was detected in 21 (8.6%) samples. Thir-
ty-six samples (14.8%) showed mixed infections, involving dif-
ferent clade and subtype combinations (Table 2). Infections
ascribed by RFLP to a unique subtype within clades 1 or 2 were
classified as follows: within clade 1, subtype 1a/c was found in
57 samples (23.4%), while subtype 1b accounted for the re-
maining 73 (30.0%); clade 2 included 47 samples regarded as
subtype 2a/c (19.3%) and 9 samples regarded as subtype 2b/c
(3.7%); within clade 3, all samples (n 5 21) were characterized
as subtype 3a/c/d/e (8.6%). No samples belonging to subtype
3b were detected.
The relative prevalence of each subtype within the different
groups studied showed interesting features since significant or
highly significant differences were observed among transfused
patients and IVDU, respectively, comparing the specific sub-
types with their prevalence within the whole population (two
unpaired proportions, two-sided test). Although two other
groups of patients showed statistically significant differences as
well, the scarce number of patients included within each of
FIG. 1. 59UTR-core RFLP. Amplicons (647 bp) were digested with AccI and
run on a 4% agarose gel which was stained with ethidium bromide. Lane a, mixed
HCV infection involving subtypes 1a (predominant) and 1b; lane b, 25-bp ladder;
lane c, subtype 1b restriction pattern.
TABLE 1. HCV genomic characterization studies performed with 243 samples
Group











59UTR RFLP only (n 5 148) 148
Concordant 59UTR RFLP analysis and 59UTR cDNA sequencingb (n 5 37) 37 37
Concordant 59UTR RFLP analysis and 59UTR cDNA sequencing but
discrepant versus core PCR (n 5 1)
1c 1 1 1
Discrepant 59UTR RFLP analysis versus core PCR (n 5 6) 6 6
Concordant 59UTR RFLP analysis and 59UTR cDNA sequencing but
nontypeable by core PCR (n 5 12)
12 12 12 12
Typed by 59UTR RFLP analysis but nontypeable by core PCR (n 5 14) 14 14
Concordant 59UTR RFLP analysis and core PCR (n 5 23) 23 23
Unrecognized subtype by 59UTR RFLP analysis (n 5 2) 2 2
Total 243 56 50 15
a Only 15 out of 34 studied sera were NS5B PCR positive.
b Four samples exhibited mixed infections by RFLP, showing the predominant population also documented by cDNA sequencing, in addition to minor HCV
population(s).
c Minor population of type 1 (plus 2a/c) was also detected in 3 out of 10 RT-nested 59UTR PCR amplifications followed by RFLP analysis of isolate 760.
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them precludes any further conclusions (Table 2). Among
transfusion patients a higher prevalence of 1b subtype (P ,
0.05) was observed. In contrast, among IVDU, the contribu-
tion of subtype 3a/c/d/e was significantly higher compared to its
own incidence within the (non-IVDU) whole population (P ,
0.01), while there was less subtype 2a/c compared to the overall
rates (P , 0.05). Interestingly, when HCV genotype 3a/c/d/e
was plotted against age, a striking contribution was ascribed to
young ([21- to 40-year old] mainly IVDU) patients (Fig. 2). A
statistically significant association was observed between sub-
type 3a with both the above-mentioned age range group and
IVDU (chi-square test: P 5 0.0026 versus the remaining sub-
jects [n 5 222] and P 5 0.0088 versus other parentally infected
patients [n 5 83]). Likewise, subtype 1a was significantly more
prevalent among the 21- to 40-year-old group compared with
the remaining age ranges (chi-square test: P 5 0.0001 versus
those ,20 years old; P 5 0.0317 versus those 41 to 60 years old;
and P 5 0.001 versus those .60 years old).
Out of the 243 HCV infected sera, 36 mixed infections
(14.8%) were detected which were predominantly 1a/c and 1b
(n 5 26; 72.2% of mixed infections). The majority of these 1a/c
and 1b mixed infections were mainly detected among sporadic
cases, which was a significant contribution compared to the
whole incidence of these subtypes among other groups (P ,
0.01). Randomly selected mixed infections were entirely con-
firmed either by HCV serologic genotyping (for mixed types,
see below) or by documentation of a unique AccI restriction
site only present among 1a isolates at the core region (Fig. 1)
(2, 3).
Primer-specific amplification of the core (core PCR). PCR
amplification using subtype-specific primers within the core
genomic region was performed as described by Okamoto et al.
(30, 31) on 56 samples (Table 1). We observed no amplification
products from 26 isolates (46.4%). Six samples exhibited dis-
cordant typing results compared to 59UTR RFLP analysis. The
subtype assignment in the remaining 24 samples was consistent
with the data obtained by RFLP. Subsequent use of an im-
proved version of this methodology (26) allowed us to detect
initially nontypeable 2c isolates (i.e., serum 874).
Sequence analysis. Fifty samples were selected for 59UTR
sequence comparison by phylogenetic analysis of clades and
types and are identified in Fig. 3. These studies demonstrated
that 35 isolates belonged to clade 1 (70%), 10 belonged to
clade 2 (20%), and 5 belonged to clade 3 (10%). However,
when results from these 50 sequenced isolates were compared
with the experimental results from 59UTR RFLP analysis it
was shown (by the latter methodology) that four samples con-
tained mixed infections (i.e., 1a plus 1b, n 5 3; 1a plus 1b plus
3a, n 5 1) composed of predominant genomes (detected by
both cDNA sequencing and RFLP analysis), in addition to
minor HCV populations detected only by RFLP analysis (Ta-
ble 1).
With regard to the NS5B isolates studied, only 15 out of 35
(42.9%) could be detected by RT-nested PCR amplification
(Table 1), reflecting the known different sensitivity to detect
HCV RNA based upon RT-PCR amplification on this region
with regard to the most conserved 59UTR (5, 49). NS5B se-
quencing and the corresponding phylogenetic analysis showed
that five samples belonged to subtype la, five samples belonged
to subtype 1b and the remaining five samples belonged to 2c
(Fig. 4). Ten out of 15 samples (66.6%) showed results con-
cordant with 59UTR RFLP analysis (see below).
Both phylogenetic trees were supported by bootstrap values
higher than 70% for clade and HCV subtype assignment, re-
spectively.
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mistyping, within samples inter se from both 59UTR and NS5B
regions was exhaustively investigated and ruled out since dif-
ferent controls confirmed the accuracy of data, with (i) RNA
from two different aliquots, (ii) cDNA bidirectionally se-
quenced, and (iii) absence of 100% homology with any other
product from the same regions.
HCV serologic genotyping. Three selected samples were
confirmed as showing mixed infections ascribed to different
genotypes (i.e., 1 plus 2, n 5 1; 1 plus 3, n 5 2).
Discrepant HCV typing results. Table 3 summarizes the
discrepancies we observed using the three different approaches
for subtype assignment where NS5B amplicons could be ob-
tained. Subtype assignment based upon 59UTR RFLP and
NS5B sequence analysis was concordant in 10 of the 15 sam-
ples. One of these discrepant samples was the initial serum
from a health care worker (sample 760) which appeared to
have a mixed population detected in the 59UTR, the minor one
of which was selectively amplified within the NS5B region
(subtype 1a). Later during infection (sample 874), the major
population (subtype 2a/c) was the only one detected in both
59UTR RFLP analysis and within the NS5B sequence analysis.
The four remaining discrepant samples were subtype la and 2c
based upon NS5B sequence analysis, but subtypes la/c, lb,
3a/c/d/e, and 2a/c based upon 59UTR RFLP analysis. Six other
samples failed to show concordant results between 59UTR
RFLP analysis and core PCR (i.e., 2a/c versus 1a; 2a/c versus
3a; la versus 3a (n 5 2); 1b and 3a versus 1a, 1b, and 3a; and
3a versus 1b and 2b, respectively), but NS5B PCR amplifica-
tion consistently rendered negative results.
5*UTR-core RFLP. Mixed infections involving 1a plus 1b
detected by 59UTR RFLP were confirmed by AccI digestion (2,
3) of amplicons from 10 randomly selected samples (Fig. 1).
Biochemical evaluation of liver function. To determine the
clinical significance of infection with different HCV genotypes,
we analyzed the relationship of serum ALT levels from 97
samples, approximately representing the same genotype distri-
bution observed in the whole population studied. Data are
shown in Table 4. No statistical difference was observed when
ALT levels from serum samples exhibiting different HCV types
or subtypes were compared. However, ALT values from pa-
tients infected with more than one type or subtype were sig-
nificantly higher than those observed in patients infected with
genotype 1 (P 5 0.0108) or 3 (P 5 0.02) but not with genotype
2; remarkably, when a specific subtype was considered, lb, ALT
values differed with high statistical significance compared to
values for mixed infections (P 5 0.0032).
DISCUSSION
These studies provide the most comprehensive data to date
on HCV subtypes present in chronically infected patients re-
ferred to medical treatment in Argentina between 1993 and
1999.
Out of 547 viremic patients, 243 sera were included within
these investigations, and the HCV genotype was determined by
RFLP analysis of the 59UTR region (9) while selected subsets
were also evaluated by primer-specific core region amplifica-
tion (30, 31) and amplification and sequencing of a fragment
derived from the NS5B genome region (6, 11).
At least four major points deserve to be highlighted: (i) the
overall HCV subtype distribution; (ii) the relatively high prev-
alence of mixed infections; (iii) the inferred high prevalence of
subtype 2c within 2a/c isolates; and (iv) the observation of
discrepant results when different HCV genomic regions were
analyzed.
Firstly, only genotypes 1, 2, and 3 were detected with de-
creasing prevalence, as shown in Table 2. Genetic analysis
using 59UTR RFLP indicates that 23.5% of infections are
subtype 1a/c, 30.0% are subtype 1b, 23.0% are subtype 2a/c or
2b/c, 8.6% are subtype 3a/c/d/e, and 14.8% are mixed infec-
tions. These results confirm and strengthen our initial data (33,
41). Thus, HCV genotype distribution in Argentina closely
resembles the reported data from other Western countries.
However, it is worth mentioning that other Argentine re-
searchers have recently observed the circulation of a small
percentage of strains ascribed to either genotype 4 or 5 among
hemophiliacs (36). The higher prevalence of clade 3 observed
among IVDU with regard to other groups studied (P , 0.01)
FIG. 2. HCV genotype distribution according to age range (years).
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FIG. 3. The phylogenetic tree shown is based on 124 sequences derived from the 59UTR of HCV. Argentine HCV sequences (n 5 50) are indicated by their isolate
numbers (in boldface type): samples 498, 594, 611, 614, 618, 619, 630, 660, 668, 726, 745, 751, 760, 768, 782, 784, 785, 789, 791, 793, 794, 803, 804, 812, 813, 818, 824,
828, 905, 906, 959, 963, 965, 969, 971, 973, 974, 976, 980, 982, 985, 986, 989, and 990 correspond to accession numbers from GenBank AF041264 to AF041313,
respectively. Sequences used as references for the phylogenetic tree (n 5 74) are identified by their accession number from GenBank. Note that major HCV clades
from 1 to 6 are indicated. The DNA alignments were generated with the Clustal X program. The phylogenetic tree was constructed with the TREEVIEW program.
Bootstrap analysis was performed by using the programs SEQBOOT (to generate 1,000 reshuffled sequences), CONSENSE, and RETREE at the midpoint of the
longest branch for comparative purposes (PHYLIP package, version 3.5c). Bar, number of nucleotide substitutions per site.
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FIG. 4. The phylogenetic tree shown is based on sequences derived from the NS5B region of HCV. Argentine HCV sequences (n 5 15) are indicated by their isolate
number (in boldface type): samples 619, 760, 794, 803, 812, 874, 959, 967, 968, 969, 974, 980, 986, 1274, and 1470 correspond to accession numbers from GenBank
AF041314 to AF041328, respectively. Sequences used as references for the phylogenetic tree (n 5 99) are identified by their accession number from GenBank. Note
that major HCV clades from 1 to 6 are indicated. Shaded boxes indicate bootstrap values. Bar, number of nucleotide substitutions per site.
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is in agreement with previous reports from Europe (35). To-
gether with a recent report from Argentina (14), these are the
first studies from another part of the world which also suggest
that IVDU may carry selective subtypes.
Secondly, the presence of HCV mixed infections is an inter-
esting field of current research. Two previous reports from the
authors showed dissimilar results at this specific point. We had
initially detected a high proportion of mixed infections, reach-
ing up to 45.4% (33), while in a later study we did not detect
mixed infections (41). These discrepancies might be explained
by considering the typing methodologies that we employed
each time. In the former, a core-based specific PCR method
was applied (30, 31), and it is known that this procedure may
readily detect different genotypes but produces a certain de-
gree of mispriming (23). In the later study, a majority of typing
results was obtained by predicted RFLP patterns from 59UTR
nucleotide sequencing. It seems plausible that only predomi-
nant genomes would have been detected, since purified PCR
products were then directly sequenced. Therefore, the exis-
tence of minor HCV populations could not be ruled out. Be-
sides, distinct populations studied exhibited differential risk of
multiple exposure to HCV sources (e. g., hemophiliacs, not
included in our second survey [41]).
In the present study, we have analyzed all samples by using
RFLP, which is reportedly known to need roughly equimolar
concentrations for detecting mixed infections implying at least
two different HCV subtypes (9). Among 243 HCV-infected
patients, 36 exhibited mixed infections (14.8%). This percent-
age is higher than the observed value for samples from other
geographic areas in previous epidemiological studies using the
same methodology (46) although it is approximately similar to
the rate reported in Venezuela (38). The possibility of RT-
nested PCR contaminations was entirely ruled out since RNA
was extracted from two separate serum aliquots and subse-
quently amplified. All RFLP results regarding the predomi-
nant viral population were in agreement with data obtained by
cDNA sequencing of the same 59UTR (n 5 50). Subtypes 1a/c
and 1b accounted for most of the mixed infections (72.2%),
although 59UTR RFLP methodology might have mistyped a
very low number of the samples due to the unusual presence of
A or G at position 299 within subtypes 1b or 1a (9). This
contribution was also observed among sporadic cases, reflect-
ing the high prevalence of these subtypes in the general pop-
ulation of Buenos Aires, Argentina.
Data regarding mixed infections were documented using
different approaches, including (i) 59UTR RFLP analysis as
mentioned above; (ii) analysis of a second genomic region
looking for a specific AccI restriction site (cleavage at nucleo-
tide 184 from the putative AUG start codon) at the core region
(n 5 10), which was reported to be indicative of subtype la
(Fig. 1, lane a, corresponding to a mixed infection involving 1a
plus 1b) but was absent among 1b isolates (Fig. 1, lane c) (2, 3);
and (iii) detecting the immune response against type-specific
NS4 peptides. Concordant results obtained were in agreement
with data already reported (27) when comparing 59UTR RFLP
analysis, NS4 serologic genotyping, and 59UTR sequencing,
which also showed 100% concordance among them.
Several hypotheses might be considered for mixed HCV
infections: (i) simultaneous coinfection with different types
and/or subtypes; (ii) superinfection of HCV-infected but non-
protected individuals, as documented in experimentally inoc-
ulated primates (29) or naturally infected patients (22); (iii)
HCV genotype turnover as observed among dialyzed (37) and
hemophilic (12, 39) patients; (iv) HCV genotype overtake phe-
nomena (which may last up to 1 to 8 months) (22); and (v)
selective replicative advantage of genotype 1 (22). Moreover, it
should be taken into account that the daily produced hetero-
geneous quasispecies belonging to a given genotype could tem-
porarily fluctuate (10, 15). The simultaneous coinfection with
different genotypes might imply a large cohort of individuals
that already have mixed infections and the efficient transmis-
sion of all strains. Conversely, if superinfection were the main
cause of mixed infections, it should be envisaged to occur more
frequently among IVDU. Since this was not the case (only 5
out of 40 patients [12.5%]) potential explanations should con-
sider both their younger age (Fig. 2) and (short) time of intra-
venous drug addiction. HCV genotype overtake phenomena
and subsequent replacement have been observed in longitudi-
nal studies of hemophiliacs (12, 39) where multiple exposures
were documented. Likewise, this fact might account for a cer-
tain percentage of mixed infections within the population stud-
ied. For unknown reasons, type 1 (and, if present, subtype 1b)
is frequently predominant in donor-recipient pairs of geno-
types when orthotopic liver transplantation patients are mon-
TABLE 3. Discrepancies among different methodologies




Core PCR 59UTR RFLP analysis NS5B sequencing
619 (SC) NTb 1a 1a
760 (HW)c 1b 2a/c 1 1d 1a
794 (SC) NT 1b 1b
803 (T) NT 2a/c 1a
812 (IVDU) NT 3a 1a
874 (HW)c NTe 2a/c 2c
959 (NONPR) NT 1a 1a
967 (IVDU) NT 1b 1b
968 (T) NT 1b 2c
969 (HW) NT 1a 1a
974 (SC) NTe 2a/c 2c
980 (NOPR) NT 1a 2c
986 (SC) NT 1b 1b
1274 (SC) NTe 2a/c 2c
1470 (T) NT 1b 1b
a SC, sporadic cases; HW, health workers; T, transfusion patients; NONPR,
nonspecified other nonparenteral risks; NOPR, nonspecified other parenteral
risks.
b NT, not typeable.
c Nucleotide sequences obtained from two different samples from the same
patient after 6 months of elapsed time.
d Minor population: type 1 (plus 2 a/c) was also detected in 3 out of 10
RT-nested 59UTR PCR amplifications followed by RFLP analysis.
e When 2c-specific primers were used, this sample became characterized. Another
group of six sera showed discrepant results between core PCR and 59UTR
RFLP, but NS5B amplification rendered negative results.






Type 1 (51) ............................................................................... 63 6 63
Subtype 1a/c (24) ..................................................................... 79 6 86
Subtype 1b (27) ........................................................................ 48 6 27
Type 2 (17) ............................................................................... 62 6 60
Subtype 2a/c (14) ..................................................................... 61 6 64
Subtype 2b/c (3) ....................................................................... 67 6 41
Type 3 (12)a .............................................................................. 62 6 54
Mixed infection (17) ................................................................ 122 6 119b
a All 3a/c/d/e.
b P 5 0.0032 versus 1b; P 5 0.0108 versus 1; P 5 0.02 versus 3.
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itored, thus suggesting a selective replicative advantage (22).
Coincidently, 29 out of 36 mixed infections (80.6%) involved
subtype 1b, a much higher rate than the overall prevalence of
such subtype within the whole population studied (P , 0.01).
Interestingly, ALT values from patients exhibiting HCV mixed
infections showed higher values than those infected with ge-
notype 1 or 3 (P 5 0.0108 and 0.02, respectively). However, a
cautious interpretation of these data is needed, considering
both the limited number of mixed infections analyzed in this
study and the usual fluctuation of ALT levels in serum during
the natural course of the infection.
Thirdly, regarding HCV type 2 assignment by NS5B se-
quence analysis, three out of three 2a/c isolates (according to
59UTR RFLP analysis) were finally ascribed to subtype 2c
(samples 874, 974, and 1274), in agreement with results ob-
tained by an improved version of the core-based typing assay
(Table 3) (26). It is concluded that this subtype might poten-
tially represent an important contribution to local HCV epi-
demiology, taking into account that (i) 23.0% of the population
studied exhibited type 2 infections (n 5 56) and (ii) both
subtypes 2a and 2b are indistinguishable from subtype 2c at the
59UTR. A high prevalence of subtype 2c has been found
among individuals in Italy (4, 16, 25, 44, 47), from which a
substantial proportion of the Buenos Aires population is de-
scended, due to immigration within this century.
Fourthly, type assignment by 59UTR RFLP and NS5B phy-
logenetic analyses exhibited concordant results in 10 of 15
cases studied (66.7%), while five samples were discrepant with
regard to the previously observed 59UTR RFLP pattern (Table
3). Discrepant results according to the analyzed HCV genomic
region have been previously reported as well (23, 27, 34). In
this regard, at least three potential explanations should be
considered: (i) the coexistence of HCV genotypes for which
primers used during RT-PCR displayed different sensitivity
and/or specificity (Table 3, see sample 760: 1b at core 2a/c plus
1 [minor population] at 59UTR, and 1a at NS5B genomic
regions); (ii) in vitro template shuffling during RT-PCR am-
plification; or (iii) hypothetical possibility of recombination
between different HCV variants showing nucleotide sequences
belonging to different genotypes throughout viral genomes, as
inferred from early reports (17, 19). In this regard, thorough
studies could not subsequently demonstrate an eventual phe-
nomenon of recombination between HCV genotypes (44, 46),
but this hypothesis remains to be further explored.
The above-mentioned five discrepant samples were assayed
by the core-based specific PCR technique (30, 31), but unfor-
tunately only one of them proved positive; therefore, the re-
maining four samples were classified as nontypeable by this
methodology. Factors such as low viral load (50) and lack of
exact complementarity between 2a primers and 2c sequences
accounted for most nontypeable samples (data not shown).
This hypothesis was confirmed when samples 874, 974, and
1274 were assayed with a 2c-specific core primer (26).
Considering some limitations of 59UTR RFLP analysis for
HCV subtyping (9, 46), despite recently proposed improve-
ments (3), it is currently agreed that it is mandatory to perform
simultaneous sequencing of coding genomic regions, which
exhibit a greater degree of nucleotide heterogeneity within a
given type (42, 45). Nevertheless, RFLP is still a widely used
tool for epidemiological studies when massive genomic analy-
sis regarding other hepatitis viruses is undertaken (24, 32, 33).
By means of different methodologies including phylogenetic
analysis, this study depicts a general view of circulating HCV
strains during 1993 to 1999 in Buenos Aires, Argentina, and
adds information on HCV molecular epidemiology in South
America (14, 20, 33, 36–39, 41). After cross-protection studies
are performed with different genotypes in primates—as previ-
ously investigated with wild-type strains (29)—potential immu-
nogens for humans are expected to be developed (1, 7, 8, 18,
51; M. Houghton, Q.-L. Choo, G. Kuo, D. Chien, A. Weiner,
M. Selby, L. Consens, S. Coates, R. Ralston, H. Davis, J.
Kansopon, K. Berger, S. Wong, M. Wininger, C. Dong, K.
Crawford, M. Chin, E. Glazer, M. Jennings, E. Muchmore, D.
Rosa, and S. Abrignani, Abstr. IX Triennial Int. Symp. Viral
Hepat. Liver Dis., abstr. 150, 1996). Our data should be taken
into account when future HCV vaccines are constructed based
upon geographical and epidemiological criteria.
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